Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multi-centre, double-blind dose-ranging study to evaluate the efficacy and safety/tolerability of Birch Modified Allergen Tyrosine-adsorbed + MPL (POLLINEX Quattro® Birch) in Subjects with seasonal allergic rhinoconjunctivitis due to birch pollen

Trial Profile

A multi-centre, double-blind dose-ranging study to evaluate the efficacy and safety/tolerability of Birch Modified Allergen Tyrosine-adsorbed + MPL (POLLINEX Quattro® Birch) in Subjects with seasonal allergic rhinoconjunctivitis due to birch pollen

Completed
Phase of Trial: Phase II

Latest Information Update: 19 May 2018

At a glance

  • Drugs Birch pollen allergy immunotherapy (Primary)
  • Indications Allergic rhinoconjunctivitis; Seasonal allergic rhinitis
  • Focus Therapeutic Use
  • Sponsors Allergy Therapeutics
  • Most Recent Events

    • 19 May 2018 Results of pooled data from two trial ((EudraCT numbers: 2012-004336-28 PQBirch203 and 2015-000984-15 PQBirch204) to determine its optimal cumulative dose of Pollinex Quattro Birch allergoid immunotherapy, were published in the Allergy.
    • 11 Oct 2014 Status changed from recruiting to completed as reported by European Clinical Trials Database.
    • 22 Sep 2014 Results published in an Allergy Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top